Gilead seeks FDA approval for COVID-19 drug remdesivir, gives it a brand name

Gilead Sciences applied for approval from the FDA for its experimental COVID-19 treatment remdesivir on Aug. 10. The drug will go by the brand name Veklury. 

Currently the drug is available in the U.S. under an emergency use authorization. It is for the treatment of hospitalized patients with severe COVID-19. 

However, securing FDA approval of its new drug application would clear the way for wider use of remdesivir.

"Today's filing is an important milestone as we continue to partner with the U.S. government and healthcare authorities around the globe to address the treatment needs of patients with COVID-19," said Merdad Parsey, MD, PhD, CMO of Gilead Sciences.


Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars